FDA Approves Product Redeeming Rare Pediatric Disease Priority Review Voucher

Summary

The FDA has approved a product, XYWAV, which was previously approved on July 21, 2020, and meets the criteria for redeeming a priority review voucher, allowing its sponsor to request expedited review of future applications.